Back

Oral HRS-5346, a novel small molecule lipoprotein(a) inhibitor, in adults at high cardiovascular risk with elevated lipoprotein(a): a phase 2, randomized, double-blind study

31 August 2026 (08:30 - 08:45)
Organised by: Logo
Congress Presentation Part of: Beyond statins: the next wave of lipid-lowering therapies Drug therapy ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Dan Zhu

Peking University Third Hospital, Beijing (China)

5 More presentations in this session

Presentation thumbnail
Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial
Professor I. Hilgendorf (Berlin, DE)
Slides Video
Presentation thumbnail
Protocol-based early intensive lipid management in patients with acute coronary syndrome (BRIDGE): A multicenter prospective cluster-randomized controlled trial
Doctor K. Oyama (Sendai, JP)
Slides Video
Presentation thumbnail
A phase 3 clinical trial to evaluate the efficacy and safety of vsa003 injection in chinese adolescents and adults with homozygous familial hypercholesterolaemia (hofh)
Doctor Z. Tian (Beijing, CN)
Slides Video
Presentation thumbnail
Effects of Evolocumab on Fatal Outcomes in Patients Without a Prior Myocardial Infarction or Stroke : Pre-specified Analysis of the VESALIUS-CV Trial
Doctor R. Giugliano (Boston, US)
Slides Video
Presentation thumbnail
Effect on Oxidized Phospholipids of Lepodisiran, an Extended Duration siRNA Targeting Lipoprotein(a)
Professor S. Nissen (Cleveland, US)
Slides Video

Access the full session

Session thumbnail
Beyond statins: the next wave of lipid-lowering therapies
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 08:30 CET
You may be interested in
thumbnail
Congress Session
Late-breaking science on pharmacology
28 August 2023
thumbnail
Congress Presentation
Extremely Long Duration Lp(a) Reduction Following a Single Dose of Kylo-11: Final Data from a First-in-Human Study
28 August 2026
thumbnail
Congress Presentation
Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability
28 August 2026
thumbnail
Congress Presentation
Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1301, an oral PCSK9 inhibitor, in healthy participants: a first-in-human, randomized, double-blind, placebo-controlled phaseⅠtrial
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources